R
RADIOPHARM THERANOSTICS LIMITED AMERICAN DEPOSITARY SHARES
NASDAQ: RADX (Radiopharm Theranostics Limited)
Last update: 14 hours ago1.08
-0.04 (-3.26%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Radiopharm Theranostics Limited | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.95 |
Select this tab to load the latest available analysis.
|
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Regal Partners Ltd | 30 Jun 2026 | 40,138 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |